Trial Profile
A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Magrolimab (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Head and neck cancer; Lung cancer; Lymphoma; Ovarian cancer; Pancreatic cancer; Salivary gland cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Forty Seven
- 21 Mar 2020 Results developing a population pharmacokinetics (PK) model of magrolimab to quantitate the effect of patient/disease charac-teristics on PK using data from SCI- CD47-001 and 5F9003 studies presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 27 Feb 2019 Results (n=62) assessing safety, tolerability, and early efficacy published in the Journal of Clinical Oncology
- 01 Feb 2019 Status changed from active, no longer recruiting to completed.